Table 1.
Characteristics of individual studies included in this review
| Author (year) | N | BMC vs. control | Mean age (years) | Mean Baseline LVEF (%) | Days from onset STEMI to BMC infusion | BMC aspiration/Sham infusion in control arm | Cell type | Number of injected cells (x108) | Volume bone marrow aspiration (mL) | Imaging modality for endpoint assessment | Days from STEMI to baseline LVEF assessment | Core lab assessment of imaging endpoint | Follow-up (months) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cao et al. (2009) | 86 | 1:1 | 51 | Tx) 41 ± 3 | 7 | No/Yes | MN BMC | 0.5 ± 0.1 | ∼40 | 2D-TTE | 7 | No | 6 |
| C) 41 ± 3 | |||||||||||||
| Grajek et al. (2010) | 45 | 2:1 | 50 | Tx) 45 ± 10 | 4–6 | No/No | MN BMC | 4.1 ± 1.8 | 80 ± 30 | EF-RNV | 4–6 | No | 6 |
| C) 43 ± 7 | |||||||||||||
| Hirsch et al. (2010) | 134 | 1:1 | 56 | Tx) 44 ± 9 | 3–7 | No/No | MN BMC | 3.0 ± 1.6 | ∼60 | MRI | 3 (2–4) | Yes | 4 |
| C) 42 ± 8 | |||||||||||||
| Huikuri et al. (2008) | 80 | 1:1 | 59 | Tx) 59 ± 11 | 3 ± 2 | Yes/Yes | MN BMC | 4.0 ± 2.0 | ∼80 | LV Angio (biplane) | During PCI | Yes | 6 |
| C) 62 ± 12 | |||||||||||||
| Janssens et al. (2006) | 67 | 1:1 | 57 | Tx) 49 ± 7 | Within 1 day | Yes/Yes | MN BMC | 3.0 ± 1.3 | 130 ± 22 | MRI | 4 (3–5) | No | 4 |
| C) 47 ± 8 | |||||||||||||
| Lunde et al. (2006) | 100 | 1:1 | 57 | Tx) 55 ± 14 | 4–8 | No/No | MN BMC | 0.7 (0.5–1.3) | ∼50 | MRI | 19 ± 4 | No | 6 |
| C) 54 ± 12 | |||||||||||||
| Plewka et al. (2009) | 60 | 2:1 | 56 | Tx) 35 ± 6 | 7 ± 2 | No/No | MN BMC | 1.4 ± 0.5 | ∼100 | 2D-TTE | 3 | No | 6 |
| C) 33 ± 7 | |||||||||||||
| Roncalli et al. (2010) | 101 | 1:1 | 56 | Tx) 37 ± 10 | 9 ± 1 | No/No | MN BMC | 1.0 ± 0.09 | ∼50 | MRI | 7 ± 2 | Yes | 3 |
| C) 39 ± 9 | |||||||||||||
| Schachinger et al. (2006) | 204 | 1:1 | 56 | Tx) 48 ± 9 | 4 ± 1 | Yes / Yes | MN BMC | 2.4 ± 1.7 | ∼50 | LV angio (biplane) | 4 ± 1 | Yes | 4 |
| C) 47 ± 10 | |||||||||||||
| Sürder et al. (2013) | 200 | 2:1 | 58 | Tx) 36 ± 10 | 5–7 | No/No | MN BMC | 1.5 ± 1.2 | 68 ± 15 | MRI | 6 (4 –8) | Yes | 4 |
| C) 40 ± 10 | 21–28 | ||||||||||||
| Tendera et al. (2009) | 200 | 2:1 | 57 | Tx) 40 ± 10 | 3–12 | No/No | MN BMC | 1.8 | 50–70 | MRI | 4–15 | No | 6 |
| C) 40 ± 9 | Selected CD34+/ CXCR4+ cells | 0.02 | 100–120 | ||||||||||
| Traverse et al. (2010) | 40 | 3:1 | 54 | Tx) 49 ± 10 | 5 ± 2 | Yes/Yes | MN BMC | 1.0 | 50–70 | MRI | 3 ± 2 | No | 6 |
| C) 49 ± 9 | |||||||||||||
| Traverse et al. (2011) | 87 | 2:1 | 57 | Tx) 49 ± 12 | 17 (16–20) | Yes/Yes | MN BMC | 1.5 ± 0.2 | 80–90 | MRI | 17 | Yes | 6 |
| C) 45 ± 10 | |||||||||||||
| Traverse et al. (2012) | 120 | 2:1 | 57 | Tx) 45 ± 11 | 3 (3–4) | Yes/Yes | MN BMC | 1.5 ± 0.2 | 80–90 | MRI | 3 | Yes | 6 |
| C) 45 ± 11 | 8 (7–8) | ||||||||||||
| Turan et al. (2012) | 62 | 2:1 | 61 | Tx) 43 ± 10 | 7 | No/No | Nucleated BMC | 96 ± 32 | ∼120 | LV Angio (biplane) | 7 | No | 3 |
| C) 45 ± 10 | |||||||||||||
| Wollert et al. (2004) | 60 | 1:1 | 56 | Tx) 50 ± 10 | 6 ± 1 | No/No | Nucleated BMC | 25 ± 9 | 128 ± 33 | MRI | 4 ± 2 | No | 6 |
| C) 51 ± 9 |
BMC, bone marrow cells; EF-RNV, ejection fraction radionuclide ventriculography; LVEF, left ventricular ejection fraction; LV, left ventricle; LV angio, left ventricular angiography; MN BMC, mononuclear bone marrow cells; MRI, magnetic resonance imaging; N, number of patients; PCI, percutaneous coronary intervention; STEMI; ST-segment elevation myocardial infarction; TTE, transthoracic echocardiogram.
Tx, treatment arm; C, control arm.